Published in Eur J Health Econ on May 16, 2010
Mapping onto Eq-5 D for patients in poor health. Health Qual Life Outcomes (2010) 1.20
Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes (2012) 0.93
Predicting health utilities for children with autism spectrum disorders. Autism Res (2014) 0.92
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes (2014) 0.88
A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes (2014) 0.81
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health Qual Life Outcomes (2015) 0.80
A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. Clinicoecon Outcomes Res (2016) 0.78
Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. Med Decis Making (2015) 0.78
Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes (2016) 0.75
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
The time trade-off method: results from a general population study. Health Econ (1996) 4.17
Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making (2006) 3.62
External validation is necessary in prediction research: a clinical example. J Clin Epidemiol (2003) 3.49
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ (2009) 2.91
Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol (2003) 2.28
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making (2006) 1.89
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health (2007) 1.78
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol (2005) 1.48
Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health (2009) 1.32
A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Med Decis Making (2007) 1.28
Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health (2008) 1.23
Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol (2004) 1.17
Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis (2007) 1.16
Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res (2004) 1.15
Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res (2006) 1.12
Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis (2006) 0.84
Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Rev Pharmacoecon Outcomes Res (2008) 0.79
A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value Health (2009) 0.78
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health (2005) 5.25
Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ (2004) 4.92
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet (2005) 4.20
Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ (2011) 3.86
Value based pricing for NHS drugs: an opportunity not to be missed? BMJ (2008) 3.33
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy (2007) 2.66
Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ (2005) 2.52
Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ (2013) 2.31
Review of statistical methods for analysing healthcare resources and costs. Health Econ (2010) 2.27
Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med (2013) 2.23
Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS (2010) 2.04
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health (2013) 1.77
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health (2013) 1.67
The electromyographic activity of thoracic paraspinal muscles identified as abnormal with palpation. J Manipulative Physiol Ther (2006) 1.39
Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics (2005) 1.27
Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke (2009) 1.15
Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. J Neurol Neurosurg Psychiatry (2010) 1.13
Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health (2005) 1.10
Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. Health Econ (2011) 1.09
The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. J Health Serv Res Policy (2007) 1.08
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J (2006) 1.05
Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care (2011) 1.03
Effects of an exercise and manual therapy program on physical impairments, function and quality-of-life in people with osteoporotic vertebral fracture: a randomised, single-blind controlled pilot trial. BMC Musculoskelet Disord (2010) 1.00
Acute rejection and chronic nephropathy: a systematic review of the literature. Transplantation (2009) 0.99
The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials (2012) 0.93
Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. Circ Cardiovasc Qual Outcomes (2009) 0.93
The "hazards" of extrapolating survival curves. Med Decis Making (2013) 0.93
Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. Int J Technol Assess Health Care (2013) 0.90
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ (2006) 0.90
Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One (2013) 0.89
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. Bioorg Med Chem Lett (2009) 0.86
Population ageing and healthcare expenditure projections: new evidence from a time to death approach. Eur J Health Econ (2013) 0.84
The effect of individually adjusted workstations on upper quadrant posture and muscle activity in school children. Work (2002) 0.84
Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health (2002) 0.83
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res (2010) 0.83
Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg Med Chem Lett (2008) 0.83
The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc (2014) 0.81
Appropriate cohorts for cost-effectiveness analysis: to mix or not to mix? Med Decis Making (2010) 0.81
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics (2007) 0.81
Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia (2014) 0.81
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides. Bioorg Med Chem Lett (2009) 0.80
Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Med (2010) 0.80
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health (2011) 0.79
Health technology assessment in the cost-disutility plane. Med Decis Making (2008) 0.79
Mobile phone use for contacting emergency services in life-threatening circumstances. J Emerg Med (2011) 0.78
Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. BMC Neurol (2011) 0.77
Physiotherapists must collaborate with other stakeholders to reform pain management. J Physiother (2012) 0.76
Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making (2007) 0.76
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. J Ophthalmol (2010) 0.75
Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Econ (2014) 0.75
Concerns regarding the ISPOR Code of Ethics for Researchers. Value Health (2004) 0.75
New BMJ policy on economic evaluations. Economic evaluations should be judged on scientific merit. BMJ (2003) 0.75
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol (2009) 0.75
Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. BMC Musculoskelet Disord (2014) 0.75
Internet-based implementation of non-pharmacological interventions of the "people getting a grip on arthritis" educational program: an international online knowledge translation randomized controlled trial design protocol. JMIR Res Protoc (2015) 0.75
CF2-bridged C60 dimers and their optical transitions. Chemphyschem (2017) 0.75
Twenty-Five Years of Health Economics: A Tribute to Alan Maynard and Acknowledgement of the Work of the Editorial Board. Health Econ (2017) 0.75
Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation. J Med Econ (2009) 0.75
Foreword. Eur J Cardiovasc Prev Rehabil (2007) 0.75
Comparative effectiveness research through the looking glass. Med Decis Making (2009) 0.75
End user and implementer experiences of mHealth technologies for noncommunicable chronic disease management in young adults: a qualitative systematic review protocol. JBI Database System Rev Implement Rep (2017) 0.75